Zymeworks (ZYME) EBT (2021 - 2026)
Zymeworks (ZYME) posted EBT of -$46.4 million for Q1 2026, down 11.75% sequentially from -$41.5 million in Q4 2025, and down 109.36% YoY from $495.1 million in Q1 2025.
Zymeworks (ZYME) EBT (2021 - 2026) Analysis & Trends
Zymeworks has reported EBT for 6 years, with the latest figure at -$46.4 million in Q1 2026.
- Quarterly EBT fell 109.36% year-over-year to -$46.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$104.0 million (up 2.99% YoY) and the FY2025 annual result came in at -$79.8 million, up 31.61% from the prior year.
- EBT declined to -$46.4 million in Q1 2026 per ZYME's latest filing, from -$41.5 million in the prior quarter.
- Over five years, EBT peaked at $320.4 million in Q4 2022 and troughed at -$72.7 million in Q1 2022.
- A 5-year average of -$13.3 million and a median of -$29.6 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2025: EBT soared 890.75% in 2022, then tumbled 133.15% in 2025.
- Over 5 years, EBT stood at $320.4 million in 2022, then plunged by 105.99% to -$19.2 million in 2023, then advanced by 7.36% to -$17.8 million in 2024, then sank by 133.15% to -$41.5 million in 2025, then dropped by 11.75% to -$46.4 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$46.4 million, -$41.5 million, and -$18.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -45.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.29 Mn |
| Mar 31, 2026 | -46.35 Mn |
| Dec 31, 2025 | -41.48 Mn |
| Sep 30, 2025 | -18.27 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | -22.14 Mn |
| Dec 31, 2024 | -17.79 Mn |
| Sep 30, 2024 | -29.62 Mn |
| Jun 30, 2024 | -37.62 Mn |
| Mar 31, 2024 | -31.58 Mn |
| Dec 31, 2023 | -19.20 Mn |
| Sep 30, 2023 | -27.58 Mn |
| Jun 30, 2023 | -49.50 Mn |
| Mar 31, 2023 | -22.96 Mn |
| Dec 31, 2022 | 320.44 Mn |
| Sep 30, 2022 | -47.88 Mn |
| Jun 30, 2022 | -64.63 Mn |
| Mar 31, 2022 | -72.70 Mn |
| Dec 31, 2021 | -40.52 Mn |
| Sep 30, 2021 | -59.82 Mn |